Free Trial
NASDAQ:CCCC

C4 Therapeutics Q4 2023 Earnings Report

C4 Therapeutics logo
$1.64 -0.10 (-5.46%)
As of 12:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

C4 Therapeutics EPS Results

Actual EPS
-$0.68
Consensus EPS
-$0.67
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

C4 Therapeutics Revenue Results

Actual Revenue
$3.26 million
Expected Revenue
$5.23 million
Beat/Miss
Missed by -$1.97 million
YoY Revenue Growth
N/A

C4 Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, February 22, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

C4 Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025

C4 Therapeutics Earnings Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Stifel Nicolaus Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)
See More C4 Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like C4 Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on C4 Therapeutics and other key companies, straight to your email.

About C4 Therapeutics

C4 Therapeutics (NASDAQ:CCCC), a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

View C4 Therapeutics Profile

More Earnings Resources from MarketBeat